专利的纤维解酶:一个概述
Yuan Cao1, Mingxuan Gou1, Abu Zar2
1Department of Microbiology, Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia.
Recent patents on biotechnology
|October 22, 2025
概括
这项研究审查了纤维解酶的专利,突出了它们的医疗潜力和生化特征. 它提供了研究趋势和专利保护在这个快速发展的领域的前性总结.
科学领域:
- 生物化学 生物化学
- 生物技术是生物技术.
- 药理学 药理学是指药理学的学科.
背景情况:
- 纤维溶解酶显示出显著的医学潜力.
- 这一领域的研究正在快速发展.
- 通过专利保护知识产权对于适用知识至关重要.
研究的目的:
- 编制和分析与纤维解酶相关的专利.
- 识别关键信息,如出版年,申请国家和专利状态.
- 通过将专利数据与文献研究结合起来,总结当前的研究状况.
主要方法:
- 在谷歌专利和Espacenet数据库中系统搜索"纤维解酶"专利.
- 分析核心专利信息:出版年份,国家,状态,酶源和生物化学特征.
- 专利数据与当前科学文献的整合.
主要成果:
- 关于纤维解酶的专利环境的全面概述.
- 识别酶源和生物化学特征的趋势.
- 专利活动与研究进步之间的相关性.
结论:
- 专利分析为纤维解酶的商业和研究轨迹提供了宝贵的见解.
- 这篇综述为该领域提供了新的,前性的视角.
- 了解专利保护是未来发展纤维解酶应用的关键.
相关概念视频
Clot Retraction and Fibrinolysis
8.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.4K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Venous Thrombosis III: Interprofessional Care
278
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
278
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Extrinsic and Intrinsic Pathways of Hemostasis
12.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
12.0K


